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Although academics have raised ethical issues with iPSCs, patients’ perspectives on them and their attitudes
toward donating biological materials for iPSC research are unclear. Here, we provide such information to aid
in developing policies for consent, collection, and use of biological materials for deriving iPSCs based on
patient focus groups.Recent high-profile cases involving the
use of human tissues in research highlight
the importance of the ethical issues
inherent to the use of archived and newly
collected tissues for the derivation of
induced pluripotent stem cells (iPSCs).
For example, the use of biological speci-
mens collected from the Havasupai tribe
for broad research purposes resulted in
considerable controversy (Mello and
Wolf, 2010). Similarly, the research use
of blood spots routinely collected from
newborns without explicit parental con-
sent has been powerfully opposed in
some settings (Couzin-Frankel, 2009).
Finally, the release of the popular book
The Immortal Life of Henrietta Lacks
(Skloot, 2010) has attracted substantial
attention to the ethical issues surrounding
the creation of immortalized cell lines and
their use in research. Despite the signifi-
cance of the issues raised by these cases,
and the fact that donation of biological
materials and consent have been studied
in other settings, there are scant data
regarding the attitudes of patients toward
the donation of biological materials spe-
cifically for iPSC research.
Popular and professional discourse has
also suggested that the discovery of iPSC
technology resolved the significant ethical
and policy concerns surrounding human
embryonic stem cells (hESCs) because
deriving iPSCs does not involve the
destruction of embryos. However, an
important array of ethical concerns
accompanies iPSC research (Sugarman,
2008) and patients’ perspectives on theseissues are wanting. Similarly, while
informed consent plays a central role in
research, and suggestions regarding the
informed consent process for iPSC
research have been offered (Aalto-Seta¨la¨
et al., 2009; Lowenthal et al., 2012), the
opinions of patients regarding donation
of biological materials for iPSC research
are unclear. Accordingly, we conducted
five focus groups with a total of 26
patients who receive medical care at the
Johns Hopkins Hospital in Baltimore,
MD to inform the development of appro-
priate policies for consent, collection,
and use of biological materials for deriving
iPSCs (Table 1). In these focus groups, we
sought patients’ views on the ethical
issues related to iPSC research, including
informed consent. Additional information
about the focus groups is available in the
Supplemental Information and Table S1,
available online.
Patients’ Attitudes
Participants generally had positive
attitudes toward and were supportive of
iPSC research. There was substantial
awareness of stem cell research and the
promise of potential stem-cell-based
therapies. Support for iPSC research
was primarily motivated by altruism, but
sometimes included the hope of personal
benefit. Nevertheless, participants had
concerns about privacy, immortalization
of cell lines, commercialization of human
tissues, and the creation of gametes.
Although participants felt that iPSC
research was associated with some prob-Cell Stem Cellematic ethical issues, they almost always
paired concerns with suggestions about
how these concerns could be mitigated
with consent, transparency, and trust.
Reasons Underlying Support for
iPSC Research
Altruism. The most common reason
participants were supportive of iPSC
research was the desire to help others.
Altruism was also the most frequent
motivating factor for the willingness to
provide tissue for iPSC research. Altruistic
sentiments among participants were wide
ranging, from wanting to help develop
therapies for their children and grand-
children to helping future generations of
people with diseases similar to their
own. For example,
Well, if you had taken some of my
cells and you’re growing it in a labo-
ratory to help somebody, I don’t
think I would have a problem with
that. I mean, if it’s going to benefit
another person, cure some type of
whatever is going on with that
person that I may be able to help
withmyself. I don’t think that Iwould
have a problem with that at all.
Some participants shared touching
personal experiences of medical prob-
lems they have encountered and the
associated effects on their quality of life,
expressing hope that stem cell research
would prevent similar problems in the
future. Others mentioned family members
who had an illness that could potentiallyl 14, January 2, 2014 ª2014 Elsevier Inc. 9
Table 1. Demographic Characteristics
Characteristic Participants, n (Percentage)
Age (years) 18–29 2 (8)
30–49 5 (19)
>49 19 (73)
Race black 18 (69)
white 7 (27)
mixed 1 (4)
Sex male 10 (38)
female 16 (62)
Income (annual) <$25,000 7 (27)
$25,000–$50,000 10 (38)
$50,000–$75,000 2 (8)
$75,000–$100,000 1 (4)
$100,000–$150,000 3 (12)
>$150,000 1 (4)
missing 2 (8)
Education finished some middle school 1 (4)
finished some high school 3 (12)
finished high school 5 (19)
finished some college 4 (15)
finished Associates degree 2 (8)
finished Bachelors degree 4 (15)
finished Masters degree 4 (15)
finished Doctoral degree 2 (8)
missing 1 (4)
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search and expressed their desire to
donate tissue in hopes of helping them.
Personal Benefit. Another reason
for support of iPSC research was the
prospect of personal benefit from new
therapies resulting from it. Although par-
ticipants seemed aware that such poten-
tial treatments were still years away from
reality, several participants described
themselves as having a debilitating illness
and expressed pronounced interest in
research that might one day be able to
alleviate their symptoms. For example, a
visually impaired participant expressed a
similar optimism: ‘‘If it was up to me, I
would like to try to see if I could deal
with my situation with an eye cell.’’
Although some participants had a dis-
ease or condition that affected their
quality of life and were hopeful that stem
cell research could help them, the
majority of participants seemed to be re-
latively healthy out-patients who were
being seen for routine medical care and
for whom hope for personal benefit was
understandably less relevant.10 Cell Stem Cell 14, January 2, 2014 ª2014Concerns about iPSC Research
Despite broad endorsement of iPSC
research, participants expressed con-
cerns over privacy, immortalization,
commercialization, and the creation of
gametes.
Privacy. There was great concern that
the donation of biological material could
lead to infringements of privacy. Some
participants worried about whether
genetic information obtained from their
tissues might affect their ability to obtain
insurance and some worried about the
risk of reidentification of their deidentified
tissues. There was fear that even with
safeguards, privacy was in danger and
that there is not much that can be done
to prevent disclosure or unapproved
access to personal information. However,
altruism seemed to trump these worries
and did not prevent participants from
wanting to donate.
While almost all participants expressed
a willingness to donate tissue if their infor-
mation was safeguarded, many balked at
the idea of having traditional personal
identifiers associated with their samples.Elsevier Inc.One such participant vehemently op-
posed the idea of her name being
attached to her tissue sample: ‘‘No, not
happening. Use the cell, don’t use the
name.’’ Others were more open to the
idea of identified tissue samples being
used but focused on the importance of
transparency and consent in this regard.
The debate around identifiability was
rich—some participants realized that
access to personal data could result
in benefits such as access to health
information about oneself or of groups
and the possibility of better matches
for tissue donation. Others, however, felt
completely uncomfortable with anyone
accessing information they considered
off-limits, even if this information could
provide potential benefits for the partici-
pant or their family.
Immortalization of Cell Lines. The idea
that donated cells would potentially live
forever was unnerving to some partici-
pants. In particular, the story about the
creation of the HeLa cell line from
Henrietta Lacks’ cervical cancer tissue,
taken without consent, was raised in four
out of the five focus groups. In addition,
participants worried about whether or
not researchers would adhere to the
terms of signed consent forms. Similarly,
some feared that it would be hard to con-
trol what cells were used for in the future:
I would be wondering if you can
keep them alive for a very, very
long time. What other things could
you do with them even if I signed a
million papers saying that you’re
not supposed to do this and
that and whatever, whatever. The
potential for that to go wrong is,
you know. I’d be very nervous.
other uses that are against what I
believe or just—what I would con-
sider evil, or whatever. Yeah, I’d
have an issue with that. Big issue.
Concerns over immortalization were
not only focused on potential inappro-
priate uses of the cells, but also on who
may profit from the cell lines if they did
eventually lead to therapies.
Commercialization. Commercialization
was one of the more nuanced concerns
that surfaced in the focus groups. Parti-
cipants struggled with who should
be compensated for providing tissues
and how any resulting profits from the
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be distributed. As with discussions
concerning the immortalization of cell
lines, participants occasionally explained
ethical issues of commercialization with
reference to HeLa cells.
What if they’re immortal? That’s
potentially a problem for me,
because I’m not immortal. So
by definition someone has use,
ownership and usage, and access
to those cells after I’m gone. And
what comes to mind—I hate to
bring this up in this institution
[Johns Hopkins]—are HeLa cells.
And how they were attained, and
then there was—from a person,
and how they were used, and are
being used commercially. And that
person obviously didn’t give con-
sent. She’s not getting reimbursed.
Her family and her descendants are
not getting reimbursed from it. So I
like the idea, in theory, but as far as
in the real world, especially since
we live in a commercial society, I
have great problems with it.
Similar concerns extended to the distri-
bution of commercialized therapies, as
well. One participant cautioned that, ‘‘It
won’t be just taken to become a money
maker and the very people who need it
the most will no longer be able to benefit
from it.’’
Participants generally accepted the
need for intellectual property rights and
profits for discoveries, but disagreed
about compensation for those whose
tissues have commercial value or are
used in research with commercial value.
For example, one participant explained:
I don’t believe that the people
should profit from any hard earned
research. They put all of the ground
work into building this thing up.
Even though it is coming from you,
it was a donation. It’s a humanitari-
an effort.
However, not all expressed this level
of selflessness:
I would want a percentage. I don’t
think my contribution did as
much—I don’t know. If they were
unique to me I guess my contribu-tion would be asmuch as the actual
researcher because he wouldn’t
have been able to create it without
my particular cells.
Creation of Gametes. The idea of iPSC-
derived reproductive cells was discom-
forting for some participants. Although
participants did not always articulate
clear reasons for why they were opposed
to the creation of gametes from iPSCs,
they nonetheless expressed strong nega-
tive feelings about this line of research.
One participant immediately discussed
the idea of cloning when asked about
the acceptability of creating gametes.
Others were more concerned about the
possibility of creating offspring from their
biological materials. For example:
If you’re getting to, well okay, let’s
take this sample and that sample,
make a sperm and egg out of
them, and make babies, that’s
obviously going to disturb a lot of
people including me. It’s like, I
could have little kids running
around and not know about it, and
that would be pretty weird.
However, at least one participant
perceived a relevant difference between
the potential for creating a new human
being and the potential to create person-
alized organs for transplantation:
Well, I said very clearly, if you can
make an egg I don’t want you to
take the egg and make a baby.
But then a kidney is different. We
have to recognize that a kidney
isn’t forming a whole person. It’s
forming an organ to save an exist-
ing life.
Mitigating Factors
Although iPSC research raised a range of
concerns for all participants, these con-
cerns could largely be addressed by
important mitigating factors, especially
consent, transparency, and trust.
Informed Consent. The idea of proper
informed consent procedures as a way
to safeguard violations of autonomy was
prominent in every focus group. Even
when participants were faced with con-
cerns about providing biological mate-
rials, they emphasized that obtaining
proper informed consent would allay theirCell Stem Cellworries. Participants wanted to know
what was going to be done to their biolog-
ical materials up front, including com-
mercialization, to enable better decision
making before providing consent. One
participant emphatically stated that once
she had given consent she did not care
what was done:
That decision should be made
before you even think about
[participating in research], as far
as I’m concerned. If I decide to do
it, then all those concerns, I’mgoing
to be thinking of the pros and cons
before I do it. Once you make
them sign a consent, then that’s
what you have to do with it.
The overarching message from partici-
pants was clear—appropriate consent
was paramount. One clearly articulated
this feeling in relation to data sharing
and privacy issues: ‘‘Once again, the
consent needs to be across the board.
Everybody needs to be on the same
page following the rules.’’
Transparency. Although it may be
difficult in practice to inform every person
who donates tissue of every potential use
of their tissues in the future, there was a
strong desire among participants to have
full disclosure of the anticipated uses.
That is, in addition to wanting to provide
informed consent before donating biolog-
ical materials, participants felt that they
had the right to know about potential
uses of their tissue.
Some participants also wanted to be
able to veto certain uses: ‘‘And just effec-
tively notify, letting the person be aware
along the way of what the intent is, what
the process is, giving them really the
authority to be in control of or make deci-
sions about, okay, whether they want to
go forward with this or not.’’
Trust. The theme of trust was evident
throughout the focus group discussions.
Participants felt anxious that even with
proper consent and transparency, re-
searchers could always disregard their
wishes and conduct research in whatever
way they pleased. In general, however,
participants trusted researchers. One
participantexplained thathisworriesabout
ethical violations were allayed by trust:
.nowadays I have pretty good
faith in experimental controls that14, January 2, 2014 ª2014 Elsevier Inc. 11
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undue pain and suffering. If there
weren’t those sort of controls in
place, then yeah, I may be con-
cerned, but I—having read up on
at least a little bit of this sort of
thing, I feel confident that it’s—my
stem cells wouldn’t be participating
in atrocities, if you will.
Implications for Future Scholarship
and Policy
Altruistic motivations, as expected from
prior studies on donation of biological
materials (e.g., Hug, 2008), were a major
theme in participants’ positive attitudes
toward iPSC research. As long as par-
ticipants could be assured about proper
consent and adherence to research regu-
lations, they felt comfortable donating tis-
sue for iPSC research to benefit society as
a whole. This altruism was often coupled
with a desire to help people who suffered
from the same conditions.
Henrietta Lacks was discussed in all
but one of our focus groups and likely
shaped many participants’ attitudes and
beliefs about iPSC research. Although
this story has attracted international
attention and may similarly affect the atti-
tudes and beliefs of others, this may point
to a potential limitation of our findings
since Mrs. Lacks was treated at Johns
Hopkins Hospital, which is also where
we recruited participants. It is unclear
whether discussion about Mrs. Lacks
would figure as prominently in focus
groups conducted at a different institution
and in a different community. Similarly, it
is unclear whether our findings regarding
concerns about providing biological
materials for iPSC research would be the
same in other locations. In addition, it
is important to remember that some of
the participants in the focus groups had
serious medical conditions, and their
broad support of this promising research
may understandably be linked to a desire
for cures and treatments. It is also impor-
tant to note that the number of partici-
pants was small, potentially limiting
our findings. Accordingly, consideration
should be given to conducting similar
research in other settings. Likewise, it
would be beneficial to conduct quanti-
tative surveys to delineate the preva-
lence of particular beliefs and concerns.
Furthermore, it would be interesting to12 Cell Stem Cell 14, January 2, 2014 ª2014learn about the baseline knowledge,
attitudes, and beliefs among patients
and then to assess changes as a conse-
quence of being given scientific informa-
tion as we did in our focus groups.
The results of such a study would be
useful in mapping the informational
needs of patients for informed consent
for iPSC research. Despite these limita-
tions and needs for additional scholar-
ship, our findings should prove useful
in guiding individuals charged with craft-
ing policies and practices regarding the
provision of biological materials for iPSC
research.
For example, participants expressed
hesitation in donating samples if the
data derived from them could be used
to discriminate against them. This hesita-
tion is especially poignant given that
Gymrek et al. (2013) were able to connect
last names of tissue donors to deidenti-
fied samples using genetic sequences
and computer inferences. Consequently,
policies and practices regarding the
donation of tissues for iPSC research
should be cognizant of the strong con-
cerns around privacy among potential
participants and should have explicit
protections in place to maintain confi-
dentiality. That said, given scientific
realities, moving forward it would be
inappropriate to promise anonymity to
those who provide biological materials
for iPSC research.
In addition, it is quite clear that those
who are likely to be asked to provide bio-
logical materials to derive iPSCs expect
transparency about anticipated uses
as well as prospective written informed
consent. While there are suggestions
regarding the possibility of truncating
traditional elaborated consent processes
for research that poses minimal risk
(Faden et al., 2013), despite the minimal
physical risk associated with obtaining
most biological materials for iPSC
research, this setting does not seem to
be the appropriate place to do so. Further,
despite the practical difficulties of
meeting patients’ desires for information
and the possibility of withdrawing consent
for particular uses of iPSCs derived from
their biological materials, researchers
should be alert to these issues so they
can notify potential donors of what is
feasible for the study at hand. Alterna-
tively, these findings could be used toElsevier Inc.prompt investigation into creative ap-
proaches to meeting these desires.
While iPSCs offer considerable scienti-
fic potential and do not require access to
or the destruction of human embryos for
their derivation, there remain a set of
ethical issues related to iPSCs, including
the consent procedures surrounding
tissue collection, the potential uses of
these tissues in research and treatment,
and the potential for commercialization
(Sugarman, 2008; Zarzeczny et al.,
2009). Nevertheless, there are reasonable
approaches to managing most of these
issues, including a robust informed
consent process, transparency about
potential uses and commercialization,
and close attention to privacy.SUPPLEMENTAL INFORMATION
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